On This #GivingTuesday Support Community Leadership in HIV Prevention

Today, UNAIDS released its World AIDS Day report, Let Communities Lead. This year’s focus on community leadership is especially important to all of us at AVAC as it lies at the heart of our work for our entire 28-year history. The UNAIDS report highlights what we and our partners have raised over the years—that communities face enormous barriers, community-led responses are under-recognized, under-resourced and in so many ways, under attack.  

From our almost 30 years of experience in HIV prevention advocacy, it’s clear that working in solidarity with communities is imperative to address the root causes of inequity. Community-led responses are essential components of the comprehensive approach needed to end the epidemic.  

At AVAC, we are incredibly proud of our history and in our collaborative work in 2023 to champion civil society and community leadership in shaping local, national and global responses.

Today, as part of #GivingTuesday, a global day dedicated to giving back, we ask you to consider supporting AVAC so that we and our partners can continue to deliver the effective and impactful advocacy that is described below—and is needed now more than ever.

Your support to AVAC now will ensure that we and our partners can continue putting people and communities at the center of our work, ensuring that the global response is connected to the real needs of affected people.

Advancing bold and innovative agendas for HIV prevention.

In September, the African Women’s HIV Prevention Community Accountability Board (AWCAB) launched its  HIV Prevention Choice Manifesto  in Kampala, Uganda. The manifesto represents a historic milestone in the power of community leadership to re-frame the global discussion around community priorities. The manifesto calls for political will and financial investment to ensure access to the prevention options that women and girls in Africa say that they want. AVAC worked closely with partners to establish this coalition and catalyze its advocacy. 

Learn more.

Supporting communities to engage in the science of HIV and process of R&D. 

The Good Participatory Practice (GPP) guidelines co-developed by AVAC and UNAIDS nearly 15 years ago have become a field-wide standard for broad and inclusive stakeholder engagement in clinical trial research. At AVAC, we train trial staff on the guidelines, support their adaptation to other fields, prepare and support advocates in applying GPP in trial communities, and engage with the research community and ethics boards to maximize their use. Our new  GPP Body of Evidence, takes this a step further, offering GPP resources to advocates that demonstrate its power, show how it can be measured and replicated, and provide GPP training, tools and connection to everyone involved in the research enterprise.

Learn more.

Improving how, when and to whom prevention is delivered.

Developing—and delivering—a rich pipeline of options for HIV prevention must be guided by community priorities that define what products are needed and how they are delivered for impact. In a new opinion editorial published today in South Africa’s Bhekisisa, AVAC’s Wawira Nyagah and Mitchell Warren lay out essential lessons to ensure that a broad range of prevention options that people want and need are developed, tested and distributed equitably, at scale and with urgency. “The world cannot afford to squander another decade through slow, fragmented rollout of life-saving HIV prevention. With longer-lasting options now becoming available… the world could finally bend the curve of HIV—but only if investment and planning for delivery are as evidence-based, person-centered and innovative as research and development in new products.”

Learn more.

Supporting a robust partner network that puts prevention on national and global agendas.

Effective coordination and balanced partnerships are key to creating a policy environment, accelerating ethical product development and advocating for equitable access to emerging health solutions. AVAC partners with a global movement of advocates to bring community voices, sustained attention and greater accountability to science, policy, funding, media, health services and regulatory processes. We are proud of the skills and power-sharing and impact-oriented advocacy that has expanded and refined prevention targets, accelerated development of guidelines and reshaped policies and programs through our long-standing Advocacy Fellows program, the Coalition to build Momentum, Power, Activism, Strategy & Solidarity (COMPASS) Africa and the Coalition to Accelerate and Support Prevention Research (CASPR).

Learn more.

Fighting to keep community priorities at the center of global health.

The Coalition of Advocates for Global Health and Pandemic Preparedness is tracking the issues, keeping civil society informed, and developing tools and resources. These efforts are essential to advocacy for an integrated and holistic approach to pandemic preparedness, which depends on safeguarding equity and building on the success of the HIV response. As founding members of the coalition, we’ve been proud to fight for community priorities in the work of ACT-A, the Pandemic Fund, the Pandemic Accord, the UN High Level Meeting on PPPR, and the development of a medical countermeasures platform. AVAC published the Advocates Guide for PPPR in 2023 as a go-to resource on the issues. 

Learn more.

It is a privilege to do the work that we do. Without communities pointing the way, the HIV response will flounder, and global health will go backwards. The strength and leadership of our partners and the communities in which we work is the foundation of our hope for HIV prevention and for global health equity. We thank you for your support.

Many thanks for your partnership, solidarity and support.

Introducing From the Lab to the Jab: A new series of advocates’ guides

AVAC is excited to launch From the Lab to the Jab, a new series of advocates’ guides that highlight key advocacy issues to ensure equitable access to safe, effective, and affordable vaccines.

Co-created as part of our USAID-supported Coalition to Accelerate and Support Prevention Research (CASPR), with additional support from the New Venture Fund, From the Lab to the Jab issue briefs provide a roadmap for advocacy to advance the development and delivery of essential vaccines for HIV, COVID-19, tuberculosis, and other global public health threats, and approaches to ensure equitable access to these life-saving vaccines.

Go to avac.org/FromLabToJab to learn about next generation vaccine research and development; the basics of mRNA technology; initiatives that support local manufacturing; and understanding and overcoming barriers that undermine equitable access to vaccines. Each brief also highlights the advocacy needed to keep these efforts on track and in line with what communities need and want. 

Stay tuned for an invitation to join the From the Lab to the Jab Webinar in January 2024, and be part of the conversation that will use these briefs to strengthen advocacy and create a roadmap to achieve key transformational priorities in global health. 

On Transgender Day of Remembrance AVAC Announces TG ROAR 2023

By Jason Rosenberg

Today, on Transgender Day of Remembrance (TDOR), as communities across the globe memorialize trans and gender nonconforming (TGNC) people targeted by violence and state-sanctioned bigotry, AVAC honors the trans community—those lost and those among us. We are committed, now more than ever, to fight these ongoing injustices and support TGNC advocates to lead on issues facing their communities.  

Riding the momentum of the release of the No Data No More Manifesto and the Trans-Inclusivity Scorecard, AVAC is relaunching TG ROAR, a program from our larger PxROAR initiative, dedicated to supporting TGNC HIV advocates in Eastern and Southern Africa. The new eight-member cohort will campaign for trans-centered, HIV research and service delivery while addressing the social, political and economic barriers that all too often stand in the way. 

Crimes against TGNC are on the rise as are rates of HIV incidence in trans populations. TGNC face unique barriers to testing, adherence to pre-exposure prophylaxis (PrEP) and maintaining viral suppression. Without meaningful trans inclusion in advocacy efforts there will be no epidemic control.  

Learn more about AVAC’s new cohort of TG ROAR advocates here

We continue to fight for transgender rights and invest in TGNC leadership to create a more equitable and just future for all.

Announcing the Good Participatory Practice Body of Evidence

We are thrilled to announce the Good Participatory Practice (GPP) Body of Evidence, a new online clearinghouse of case studies and analyses demonstrating the power of GPP, along with tools, templates and trainings for GPP implementation. The resources we’ve gathered for this much-needed “one-stop GPP shop” can be used to show the impact of GPP to date, how it can be measured going forward, and its practical application in real-time.  

The Good Participatory Practice Guidelines have been shaping and improving HIV prevention research since 2007. They provide a global reference guide for ethical and effective stakeholder engagement, helping ensure the priorities of trial participants and their communities are centered in clinical trials and broader research agendas.  

Over the past 16 years, the original GPP guidelines for HIV prevention have been issued in 10 languages and adapted to other disease areas, including tuberculosis, COVID-19, and emerging pathogens. GPP has given rise to a robust global community of practice, with an expansive history of lessons learned and success stories for the world to build upon. 

But GPP implementation is far from easy. Because GPP looks different in every context and outcomes can be difficult to quantify, engagement work is often seen as secondary to clinical processes, and therefore undervalued and under-resourced. The GPP Body of Evidence demonstrates the contribution of GPP to the research enterprise, and the professionalization of GPP implementation. 

Rest assured that this is not a one-off effort! Stay tuned for a webinar series in 2024 with key partners including WHO and Wellcome Trust that will highlight critical issues in stakeholder engagement in research, linking to corresponding resources from the Body of Evidence. And we’ll be keeping the Body of Evidence up to date – so please reach out if you have resources to add.  

It’s time for GPP to become an international standard for clinical research. Making that case and making it happen, using the GPP Body of Evidence, has never been easier.  

New Resources & Upcoming Webinars

AVAC has a package of resources, and updates to share on cross-cutting issues facing advocates who care about global health equity and HIV prevention. From discussions on PEPFAR reauthorization, to an evolving picture on sexually transmitted infections, to the latest on the Pandemic Accord, to must-read and must-listen to updates on the state of the field and the state of access to new PrEP options, we’ve got it all. Scroll down for the latest and be sure to mark your calendars for five important webinars coming up this month!

Article: Progress Against HIV and AIDS is Fragile

Ahead of World AIDS Day, Mitchell Warren spoke with POZ Magazine for a comprehensive look at where we are in the fight against HIV/AIDS and what advocacy and scientific breakthroughs are needed in ending the epidemic. “I think a lot about the progress we’ve achieved in providing ARVs worldwide, about what the global HIV response contributed to the COVID-19 response and continues to contribute to current conversations about preparing for future pandemics. It’s remarkable… And yet that progress has not been equitable and is not yet sustainable. What we’ve achieved today could slip away so quickly…” 

add alternative text for the image

PxPulse Podcast: Inclusion of Pregnant and Lactating People in HIV Research

The newest episode of our PxPulse podcast is out now! In this episode, experts discuss why pregnant and lactating people have been excluded from HIV research in the past, and what needs to change. The podcast features Anne Drapkin Lyerly of the PHASES Project, a participant from the HPTN 084 trial in Zimbabwe, Ashley Lima of USAID, Takunda Sola of the Zimbabwe MoH AIDS/TB Unit and AVAC’s Manju Chantani-Gada and Jeanne Baron. 

Bhekisisa Podcast: The Anti-HIV Jab is Coming to South Africa

Advances in HIV prevention represent a huge opportunity to help get actual prevention choices into the hands of people. Listen to this podcast with Bhekisisa’s Mia Malan and in conversation with Mitchell Warren as they breakdown the complexity of issues in getting cabotegravir for PrEP available to those who want and need it as fast as possible. 

Webinar Recording: Boo, Syphilis is Really Back!

AVAC, NACCHO and NNPTC also hosted a webinar on the increasing rates of Syphilis rates to share learnings on how others are addressing these rising rates and the techniques clinicians are using to detect, treat, and prevent infections. 

Webinar Recording: Results from STI Landscaping Analyses in East and Southern Africa

Earlier this year, AVAC awarded seven teams funding to conduct projects in Southern and Eastern Africa to help understand the needs and evolving landscape around STI vaccines, diagnostics, and advocacy. These teams shared their findings and insights on two webinars that are not to be missed. Be sure to listen to the recordings, and to stay up to date with other STI events and resources by subscribing to our newsletter and visiting www.stiwatch.org.

Publication: Motivating Demand for the Dual Prevention Pill (DPP)

Multipurpose prevention technologies (MPTs) combining contraception with HIV prevention offer promising solutions to the challenges of adherence and uptake we’ve seen with oral PrEP. This new manuscript published in Frontiers in Reproductive Health by AVAC’s Wawira NyagahKate Segal and partners shares findings to support a demand generation approach for the DPP (Dual Prevention Pill).

Webinar Recording: Where We Are in the PEPFAR Reauthorization

The reauthorization of PEPFAR—a program that just surpassed 20 years, has been a hot button topic both in the US and abroad. Listen to Practicality Over Panic: What Happens if PEPFAR is not Reauthorized, a candid discussion hosted by the Global Health Council and Global AIDS Policy Partnership and including AVAC’s Richard Muko on where things are at. And don’t miss AVAC’s PxPulse podcast episode, PEPFAR at 20: Keeping the promise, which explores important successes of PEPFAR and why the bipartisan program has been so fundamental in ending the epidemic.

Webinar Recording: HIVR4P Preview

Ahead of the HIVR4P conference in 2024, and the 5th HIV Research for Prevention Conference, experts previewed some of the HIV prevention science to expect at these meetings. Be sure to check out the recordings on three important topics: Implementation and rolling out of CAB-LA; Insights into HIV vaccine research; and the future of bNAbs. 

Analysis: What You Need to Know About the Pandemic Accord

Negotiations around the Pandemic Accord are ongoing. Join us November 21 as we explore what’s in the Accord, what are the stakes, how can civil society engage, how will it affect our work. And to help make sense of it all, read the analysis by the Coalition of Advocates for Global Health and Pandemic Response, which is a compilation of recommendations from civil society and community organisations on the draft Negotiating Text of the WHO convention, agreement or other international instrument on pandemic prevention, preparedness, and response. 

Mark Your Calendars: Upcoming Webinars

November 15, HPTN 096: Building Equity Through Advocacy – An Integrated, Status-Neutral Approach for Ending the Epidemic Among Black Gay Men in the South 
Join The Choice Agenda and partners for a fascinating discussion about a novel, much-needed HIV prevention research study – HPTN 096. Currently in the field, the study addresses social, structural, institutional, and behavioral barriers to HIV prevention and care. Co-sponsored by PrEP in Black America and Federal AIDS Policy Partnership Research Working Group.Register here

November 15: Let’s Talk About HIV Cure Research
Join Dr. Marina Caskey of Rockefeller University and members of the REACH Community Advisory Board as they review the current state of HIV cure research. This webinar is for any person interested in learning about what makes curing HIV so challenging, the strategies being pursued, and what is happening in NYC! Register here. A follow-on webinar is scheduled for November 29

November 20: PrEP Resources Showcase 
Join AVAC and partners for a dynamic, workshop-style event exploring a digital collection of tools and resources on PrEP planning, access, trends in implementation research, and initiations to support robust access to PrEP and HIV prevention. Click here to register and learn more

November 21 to 24: Africa Health R&D Week 2023
Coalition to Accelerate & Support Prevention Research (CASPR) partners AVAC and IAVI are hosting the second Africa Health R&D Week November 21 through 24. The virtual forum will focus on the need for sustainable support for vaccine development and manufacturing in Africa, including through domestic resources mobilization. More information and registration are available here.

November 28: Spotlight on New PrEP Tools and Data: From R&D to access 
Between the recent accelerated growth in global PrEP initiations, and the introduction of new PrEP products like cabotegravir and the dapivirine vaginal ring, the field of PrEP data has never been more exciting or more complex. Join AVAC, the Medicines Patent Pool (MPP), and Unitaid to learn more about three important online PrEP resources and understand how they can support and enhance your work. 

New Episode of the Px Pulse Podcast

The intersection of HIV research and pregnancy

AVAC’s Px Pulse podcast has a new episode: Inclusion of Pregnant and Lactating People in HIV Research: What you need to know. 

People who are pregnant or lactating (PLP) have historically been excluded from research because of concerns for the developing fetus. But this has led to a dearth of data on new interventions against health threats for this population. In the case of HIV, pregnancy raises the risk of acquiring HIV by up to three times, but providers often do not have the data to know whether a new intervention is safe or how it will work for pregnant patients. As a result, PLP and their physicians are left to make difficult decisions around the use of proven HIV prevention products as they await more data specific to pregnancy and lactation. 

But change is in the air. Champions for the inclusion of PLP in research are paving the way for a paradigm shift— one that will redefine this population from needing protection from research to being better protected through research. In this episode of Px Pulse, AVAC’s Manju Chatani-Gada takes us through conversations with a trial participant who became pregnant, researchers, policy-makers and donors to understand why this population gets excluded, the impact it has, and what to do about it.   

Tune in to hear

  • Dr. Anne Drapkin Lyerly, Principal Investigator of the PHASES Project to advance equitable inclusion of pregnant women in HIV research and its follow-on project, PREPARE, focused on ethical HIV research in adolescents who are pregnant.  
  • Elisia Madende, Trial participant in the HPTN 084 trial in Zimbabwe
  • Dr. Ashley Lima, Health Science Specialist and Lead Technical Advisor for Socio-behavioral Research – USAID Office of HIV/AIDS Research Division 
  • Dr. Takunda Sola, HIV Prevention and Key Populations Medical Officer- Zimbabwe MoH AIDS/TB Unit 

Advocacy resources 

Essential Tools for PrEP Planning and Advocacy!

More HIV prevention options are finally becoming available, including oral pills, injections and vaginal rings. Developing and delivering these options and making them actual choices for people, while also continuing to invest in the development of additional options to meet diverse needs has never been more promising or complex.  

At AVAC, we know that products don’t end pandemics unless they are delivered with equity and urgency. We created PrEPWatch.org in 2007 to serve as a go-to resource for PrEP research, and it has expanded to include toolkits, guides, data, case studies and more to support efforts to improve access to PrEP. Our data, evidence and insights, based on lessons from oral PrEP, are intended to help get the rollout of next generation right this time. 

Please join us and partners for a series of interactive sessions to guide you through these essential resources. 

November 20, PrEP Resources Showcase

Calling for collaboration: This dynamic, workshop-style showcase is the first in a series that will feature multi-media presentations to take you through key resources including a toolkit to ensure programs related to sexual and reproductive health (SRH) and HIV prevention are well designed to reach and support adolescent girls and young women; and a comprehensive database for tracking PrEP uptake, implementation research and other critical data by country. Participants will get to dive deeply into specific resources, explore how they might use these in their work, and have an opportunity to provide input on what resources are still needed.

Register here.

November 28, Spotlight on New Tools and Data: From R&D to Access

add alternative text for the image

Staying on top of the latest data on PrEP initiations, the introduction of new PrEP products and the upstream pipeline of PrEP research and development is also both essential and complex. Advocates, researchers, funders and others working in HIV prevention must understand the trends and updates to do their job effectively—but how can you navigate the vast amount of PrEP data online?

Join AVAC, Unitaid, and the Medicines Patent Pool (MPP) to learn more about three complementary online PrEP resources and understand how they can support and enhance your work: PrEPWatch.orgLong-Acting Therapeutics Patents and Licenses Database (LAPaL) and the Access to Medicines Tracker — quarterly-update on regulatory filings, regulatory approvals and product supplies of MPP-licensed generic medicines at the country level.

Register here.

Advances in HIV prevention represent a huge opportunity to help get actual prevention choices into the hands of people. We are grateful to support from the Gates Foundation for the Biomedical Prevention Implementation Collaborative (BioPIC) and from USAID and PEPFAR for the Maximizing Options to Advance Informed Choice for HIV Prevention (MOSAIC) Consortium that help make these resources possible.

We hope you’ll join us as we walk through ways you can use our resources to make this happen.

Vital Conversations in October and November: So many webinars, so little time!

The October and November calendar of webinars offers a wealth of conversations on cross-cutting issues facing advocates who care about global health equity and HIV prevention. From discussions on PEPFAR reauthorization, to an evolving picture on sexually transmitted infections, to case studies on new interventions at the intersection of HIV prevention and family planning, to research on barriers to care and health priorities for Black gay men in the US; it is a season for advocates to engage in shaping an agenda for 2024.  

Scroll down for details and see you online! 

October 26, Practicality over Panic: What happens if PEPFAR isn’t reauthorized? 

At 11:00 AM ET: Join the Global AIDS Partnership (GAPP) for a candid assessment of the current landscape around PEPFAR, including the implications for work on the ground. It is intended to redirect anxiety into action and provide a reality check: PEPFAR is not going anywhere any time soon.

REGISTER

October 31, Boo, Syphilis is Really Back!

At 1:00 PM ET: Syphilis rates have increased drastically in recent years. Learn how others are addressing these rising rates and the techniques clinicians are using to detect, treat, and prevent infections. Co-hosted with NACCHO and NNPTC.  

REGISTER

November 7, Results from STI Landscaping Analyses in East and Southern Africa—Part 1 

At 9:00 AM ET: Hear results from STI landscaping projects conducted by AVAC partners in seven different East and Southern African countries that explored needs for STI vaccines and diagnostics.  

REGISTER

November 9, Results from STI Landscaping Analyses in East and Southern Africa—Part 2

At 8:00 AM ET: Hear results from STI landscaping projects conducted by AVAC partners in seven different East and Southern African countries that explored needs for STI vaccines and diagnostics. 

REGISTER

November 9, Pioneering Self-care Solutions to Drive Access to HIV Prevention and Family Planning 

At 8:00 AM ET: This session will amplify lessons from five self-care interventions in family planning and HIV prevention — with case studies on specific interventions— DMPA-SC; the Caya Diaphragm; the Dual Prevention PillHIV self-testing; and Triggerise; an mHealth platform. Learn more about how these successful self-care strategies can be applied across diverse settings and join the discussion on the future of self-care in sexual and reproductive health. This session is part of the 2023 Self-Care Learning and Discovery Series. Learn more here

REGISTER

November 15, HPTN 096: Building Equity Through Advocacy – An Integrated, Status-Neutral Approach for Ending the Epidemic Among Black Gay Men in the South

At 10:00am ET: Join The Choice Agenda and partners for a fascinating discussion about a novel, much-needed HIV prevention research study – HPTN 096. Currently in the field, the study addresses social, structural, institutional, and behavioral barriers to HIV prevention and care. Visit the study website here. See the speakers list here. Co-sponsored by PrEP in Black America and Federal AIDS Policy Partnership Research Working Group 

REGISTER

Announcing 5 New Advocacy Projects Devoted to Advancing Cure Research!

AVAC is excited to announce five new awards to accelerate advocacy for cure research.   

Five alumni from AVAC and the International AIDS Society’s renowned Advocacy-For-Cure Academy program will now receive 10-month, $10,000 fellowship awards, to identify local needs and create solutions that advance HIV cure research in their local context. These fellowships are part of the overall Advocacy-For-Cure Academy, which is a training program to prepare a generation of cure advocates to fight effectively for research that matters to the people who are most impacted by HIV. Launched in 2018 by AVAC and IAS, this program has supported 96 alumni to attend five academies. To learn more about the academy program click here

The first fellowships were issued to Cure Academy alumni in 2019 who have since developed training tools like the Series of Jojo, built partnerships between traditional healers and local researchers and promoted better understanding and translation of cure research by journalists.  

Advocates and community leaders play an important role accelerating ethical research and creating an enabling environment that allows research to thrive. These fellows are building awareness among key stakeholders about the current landscape of HIV cure research and supporting the growing movement to build a cure agenda led by countries most affected by HIV.  

Learn more about the newest cohort of fellows below. 

Josephine Achieng 

Josephine’s project uses a collaborative approach to promote HIV cure information and education for sex worker and other key population (KP) community advocates and health care workers for inclusive access to potential cures. Her project builds on former grantee Philister Adhiambo’s project to raise awareness and support among key populations. The project goal is to promote and strengthen efforts towards HIV cure research in Nairobi, Kenya. 

Charles Brown 

Charles’ HIV cure research advocacy focuses on increasing the participation of the community, policy makers and funders in HIV cure research engagement in Uganda. Charles will conduct interactive dialogues with HIV cure researchers to share information and simplify the HIV cure science while sharing opportunities to get engaged in the science. Charles will also build on advocacy efforts by past academy alumni to advance his work.  

Gastón Devisich 

Based in Buenos Aires, Argentenia, Gaston will work with regional alumni of IAS’ Research-for-a-Cure Academy and leading advocates and researchers to build The Latin American and the Caribbean HIV Cure Consortium. The Consortium will integrate and shed light on the work being conducted in the region and enhance collaborations to develop efficient, productive research and a strong advocacy agenda — producing a regional repository of HIV cure related resources in Spanish and Portuguese and a 2-year advocacy roadmap for the region. 

Doreen Moraa 

Doreen’s “”RAYS of Progress” is an HIV cure literacy project that aims to empower adolescents and young people living with HIV (AYPLHIVs) by delivering accessible information about current HIV cure research through social media platforms. She plans to meet with key stakeholders to elevate the importance of HIV cure research in Kenya. Her project, encompasses the aspect of hope, simplifying scientific concepts, encouraging involvement, and addressing stigma while showcasing the beauty of science in HIV cure research. 

Kennedy Mupeli 

Kennedy’s project aims to enhance cure literacy and advocacy skills among HIV long-term survivors  (HTLS) in four regions of Botswana by training 40 participants in basic HIV and cure science. HTLS, who have lived with HIV for decades, provide invaluable insights into the disease’s progression and resilience, underscoring the importance of their inclusion in research. From this group, four core HIV Cure Champions will receive further advocacy training in cure research, targeting both local and national levels, and will lead a National Cure Advocacy Academy to build a Botswanan agenda. 

These projects have been funded through the generous support of Aidsfund.

STIWatch Newsletter, October 2023

AVAC’s STIWatch newsletter is a curated resource on the latest in STI vaccines, diagnostics, and other prevention tools and strategies. 

STIs and HIV are commonly linked and impact similar priority populations including young people, gay, bisexual, and other men who have sex with men, transgender people, and those living with HIV. To end the AIDS epidemic, there is great need to better prevent, detect, and treat STIs as having an STI can make it easier to get HIV. However, STI research and development lags behind HIV efforts, highlighting a need for new options and programs to better address both epidemics.  

In 2022, AVAC launched an STI advocacy program to mobilize advocates to accelerate the development and equitable implementation of new STI vaccines, diagnostics, and other prevention options. Through this quarterly newsletter, we hope to share valuable information that sparks advocacy for a robust pipeline of interventions for STI prevention.  

New Resources

Visit STIwatch.org, AVAC’s updated and expanded online resource to understand and advocate for research, development and rollout of STI vaccines and diagnostics. This site features updates on the status of vaccines and diagnostics for curable STIs including:  

  • Information on chlamydia, gonorrhea, syphilis, trichomoniasis, and more. 
  • An STI clinical trials dashboard that provides information about trials focused on STI vaccines, diagnostics, and DoxyPEP. 
  • Updated graphics on the state of STI vaccines and diagnostic development. 

STI Advocacy Updates

To understand the needs and evolving landscape around STI vaccines, diagnostics, and advocacy, AVAC awarded seven teams funding to conduct projects in South and Eastern Africa. Congratulations to Nyanza Reproductive Health Society in Kenya, Lesotho Network of AIDS Service Organizations in Lesotho, JournAIDS in Malawi, HIV Survivors and Partners Network in South Africa, ACTS 101 in Uganda, Latu Human Rights Foundation in Zambia, and Pangaea Zimbabwe in Zimbabwe.  

These projects will help shed light on community needs and perceptions around STI advocacy; better understand issues and opportunities related to local STI vaccine and diagnostic research and development and identify areas to improve STI prevention efforts. Read more about the grantees and their landscaping work and join the webinar below.  

Upcoming Events

What We’re Reading

  • JournAIDS calls for increased focus on STIs in Malawi. JournAIDS Program Manager, Dingani Mithi, recently spoke about results from an STI landscaping report that identified challenges and opportunities to improve STI prevention in Malawi. As STIs can increase HIV transmission, Mithi discussed the need for increased STI screening, treatment, and education programs to reduce HIV burden. 
  • ASHM’s 2023 consensus statement on doxycycline prophylaxis (DoxyPEP). ASHM provides DoxyPEP recommendations for community and clinicians along with recommendations for research, guidelines, and policy. These recommendations are intended for gay, bisexual, and other men who have sex with men in Australia to prevent syphilis, chlamydia, and gonorrhea. Using DoxyPEP for a pre-defined period, continuing to promote STI screening, and the need for additional molecular tests to monitor AMR are all discussed within this guide.  
  • Centers for Disease Control and Prevention (CDC) Request for Comment on Guidelines for the Use of Doxycycline Post-Exposure Prophylaxis for Bacterial STIs. The CDC is requesting comments on recently released draft guidance on the use of DoxyPEP to prevent chlamydia, gonorrhea, and syphilis infections among gay, bisexual, and other men who have sex with men, and transgender women. This is an opportunity for advocates to provide feedback on guidelines that will shape clinical practices. Comments are being accepted through November 16, 2023 so share your thoughts today! 

Learn More

To learn more about AVAC’s STI Program, visit STIwatch.org and avac.org/sti. Email [email protected] for questions or additional information. And to sign up for specific updates on STIs, click here.